Drugs / SCB-2020S
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05228314 | May → Sep 2022 | COVID-19 | Clover Biopharmaceuticals AUS Pty | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04950751 | Aug 2021 → Apr 2022 | COVID-19 | Clover Biopharmaceuticals AUS Pty | Withdrawn | No outcome recorded Stop: Business |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-05-31 | Clover Biopharmaceuticals AUS Pty | Clover Doses First Participants in Phase 1 Trial with SCB-2020S, a Potentially Broadly Protective Chimeric COVID-19 Vaccine Candidate cloverbiopharma.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCB-2020S | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04950751 ↗ |
| Modality | Vaccine | “a recombinant SARS-Co-2 trimeric S-protein (from B.1.351 variant) subunit vaccine for COVID-19” NCT04950751 ↗ |
| Route | Intramuscular | “participants will receive two intramuscular (i.m.) injections” NCT04950751 ↗ |